STOCK TITAN

Hepion Pharmaceuticals Inc - HEPA STOCK NEWS

Welcome to our dedicated news page for Hepion Pharmaceuticals (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hepion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hepion Pharmaceuticals's position in the market.

Rhea-AI Summary
Hepion Pharmaceuticals CEO to participate in panel discussion at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
conferences
-
Rhea-AI Summary
Hepion Pharmaceuticals announces results from a study testing rencofilstat on 850 cancer cell lines, with 26% showing anti-cancer responsiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
Rhea-AI Summary
Hepion Pharmaceuticals announces new research findings on anti-cancer activity of lead drug candidate
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
none
Rhea-AI Summary
Hepion Pharmaceuticals announces positive results from a translational research study on rencofilstat in IPF tissues
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Summary
Hepion Pharmaceuticals appoints Stephen Harrison as Consultant Medical Director, replacing Todd Hobbs as Chief Medical Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Summary
Hepion Pharmaceuticals announces that its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, and its Quantitative Systems Pharmacologist, Caroline Zhao, PharmD, will present at the 2023 Canadian Society for Pharmaceutical Sciences Annual Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.3%
Tags
AI
-
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial on May 22, 2023. The trial focuses on the treatment of fibrotic diseases, including NASH and HCC. Interested parties can participate in a conference call at 8:30 a.m. ET on May 22 to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Hepion Pharmaceuticals Inc

Nasdaq:HEPA

HEPA Rankings

HEPA Stock Data

9.50M
3.86M
0.39%
17.23%
1.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Edison

About HEPA

hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.